[Temporary Announcement] Shengao Pharmaceutical: Announcement of Resolutions of the First Meeting of the Fifth Board of Directors

Announcement number: 2026-026

Securities code: 831332 Securities abbreviation: Shengao Pharmaceutical Sponsoring broker: Jianghai Securities

Chongqing Shengao Biochemical Pharmaceutical Co., Ltd.

Announcement of Resolutions of the First Meeting of the Fifth Board of Directors

The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.

1. Meeting convening and attendance

(1) Meeting status

1. Meeting time: May 11, 2026

2. Meeting method: √On-site meeting □Electronic communication meeting

3. Meeting place: company conference room

4. Time and method of issuing board meeting notice: in writing on May 6, 2026 5. Meeting host: Director Liao Daiping

5. Personnel attending the meeting: supervisors and senior managers

6. Explanation on the legality and compliance of the convening situation:

The convening, holding and resolution review procedures of this meeting complied with the provisions of the Company Law and other relevant laws, administrative regulations, departmental rules, normative documents and the Articles of Association.

(2) Meeting attendance

The meeting should be attended by 5 directors, and 5 directors should be present and authorized to attend.

2. Proposal review status

(1) Consideration and approval of the "Proposal on the Election of the Chairman of the Fifth Board of Directors of the Company" 1. Contents of the proposal:

Announcement number: 2026-026

The election of members of the company's fifth board of directors has been reviewed and approved at the 2025 annual shareholders' meeting. In accordance with the relevant provisions of the Company Law and the Articles of Association, Mr. Liao Daiping is elected as the chairman of the company's fifth board of directors, with a term of three years, starting from the date of review and approval by the board of directors and ending on the expiration date of the company's fifth board of directors. Mr. Liao Daiping holds 23,492,000 shares of the company, accounting for 98.71% of the company’s share capital. He is not a target of joint punishment for breach of trust, and there is no situation in which he is prohibited from serving as chairman of the board of directors as stipulated in the Company Law and other laws and regulations.

2. Avoidance of voting:

This proposal does not involve related transactions and there is no need to avoid voting.

3. Voting results for the motion: 5 votes in favor; 0 votes against; 0 abstentions.

4. Submit the voting status of the shareholders’ meeting:

This proposal does not need to be submitted to the shareholders' meeting for review.

(2) Consideration and approval of the “Proposal on the Appointment of Senior Management Personnel of the Company”

1. Contents of the motion:

The election of members of the company's fourth board of directors has been reviewed and approved at the 2025 annual shareholders' meeting. In accordance with the relevant provisions of the Company Law and the Articles of Association, Ms. Yang Xiuhua is appointed as the company's general manager, Mr. Liao Weidong is appointed as the company's deputy general manager, Mr. Chen Dang is appointed as the company's deputy general manager, Ms. Wang Dongmei is appointed as the company's financial director, and Ms. Yang Xiuhua is appointed as the company's board secretary. The above-mentioned personnel have a three-year term, starting from the date of review and approval by the board of directors and ending on the expiration date of the fifth session of the company's board of directors. The above personnel are not targets of joint punishment for breach of trust, and there are no circumstances in which they are prohibited from serving as senior managers as stipulated in the Company Law and other laws and regulations. 2. Avoidance of voting:

This proposal does not involve related transactions and there is no need to avoid voting.

3. Voting results for the motion: 5 votes in favor; 0 votes against; 0 abstentions.

4. Submit the voting status of the shareholders’ meeting:

This proposal does not need to be submitted to the shareholders' meeting for review.

3. Documents for reference

"Resolution of the First Meeting of the Fifth Board of Directors of Chongqing Shengao Biochemical Pharmaceutical Co., Ltd."

Announcement number: 2026-026

Board of Directors of Chongqing Shengao Biochemical Pharmaceutical Co., Ltd.

May 12, 2026